Variant of the CHEK2 gene as a prognostic marker in glioblastoma multiforme

Neurosurgery

Volumn 59, Issue 5, 2006, Pages 1078-1085

  Simon, Matthias ^a,c   Ludwig, Michael ^a   Fimmers, Rolf ^b   Mahlberg, Ralph ^a   Müller Erkwoh, Angelika ^a   Köster, Gertraud ^a   Schramm, Johannes ^a  

^a UNIVERSITY OF BONN   (Germany)

^b Institute for Medical Statisticsand Informatics   (Germany)

^c Department of Neurosurgery ^*  (Germany)

Author keywords

CHEK2 gene; Chromosome 22; Glioblastoma multiforme; Loss of heterozygosity; Prognosis

Indexed keywords

CHECKPOINT KINASE 2;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEK2 GENE; CHROMOSOME 22Q; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA POLYMORPHISM; FEMALE; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE;

BIOLOGICAL MARKERS; BRAIN NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GLIOBLASTOMA; HUMANS; MALE; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; RISK ASSESSMENT; RISK FACTORS; STATISTICS; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VARIATION (GENETICS);

EID: 33845212332     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000245590.08463.5B     Document Type: Article

References (37)

1. Bartek J, Lukas J: Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3:421-429, 2003.
2. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA: Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286:2528-2531, 1999.
3. Buckner JC: Factors influencing survival in high-grade gliomas. Semin Oncol 30:10-14, 2003.
4. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479, 1998.
5. Chen YY, Takita J, Tanaka K, Ida K, Koh K, Igarashi T, Hanada R, Kikuchi A, Tanaka Y, Toyoda Y, Hayashi Y: Aberrations of the CHK2 gene are rare in pediatric solid tumors. Int J Mol Med 16:85-91, 2005.
6. Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, Zlowocka E, Lenner M, Grabowska E, Nej K, Castaneda J, Medrek K, Szymanska A, Szymanska J, Kurzawski G, Suchy J, Oszurek O, Witek A, Narod SA, Lubinski J: CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75:1131-1135, 2004.
7. Erichsen HC, Chanock SJ: SNPs in cancer research and treatment. Br J Cancer 90:747-751, 2004.
8. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354, 2000.
9. Hartmann C, Numann A, Mueller W, Holtkamp N, Simon M, von Deimling A: Fine mapping of chromosome 22q tumor suppressor gene candidate regions in astrocytoma. Int J Cancer 108:839-844, 2004.
10. Haruki N, Saito H, Tatematsu Y, Konishi H, Harano T, Masuda A, Osada H, Fujii Y, Takahashi T: Histological type-selective, tumor-predominant expression of a novel CHK1 isoform and infrequent in vivo somatic CHK2 mutation in small cell lung cancer. Cancer Res 60:4689-4692, 2000.
11. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005.
12. Hirose Y, Katayama M, Mirzoeva OK, Berger MS, Pieper RO: Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res 65:4861-4869, 2005.
13. Hofmann WK, Miller CW, Tsukasaki K, Tavor S, Ikezoe T, Hoelzer D, Takeuchi S, Koeffler HP: Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias. Leuk Res 25:333-338, 2001.
14. Ino Y, Wahrer DC, Bell DW, Haber DA, Louis DN: Mutation analysis of the hCHK2 gene in primary human malignant gliomas. Neurogenetics 3:45-46, 2000.
15. Ino Y, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Jhung S, Ramsay DA, von Deimling A, Louis DN, Cairncross JG: Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg 92:983-990, 2000.
16. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215-225, 2002.
17. Kleihues P, Ohgaki H: Primary and secondary glioblastomas: From concept to clinical diagnosis. Neuro-oncol 1:44-51, 1999.
18. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R: Multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 95:190-198, 2001.
19. McPherson JP, Lemmers B, Hirao A, Hakem A, Abraham J, Migon E, Matysiak-Zablocki E, Tamblyn L, Sanchez-Sweatman O, Khokha R, Squire J, Hande MP, Mak TW, Hakem R: Collaboration of Brca1 and Chk2 in tumorigenesis. Genes Dev 18:1144-1153, 2004.
20. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR; CHEK2-Breast Cancer Consortium: Low-penetrance susceptibility to breast cancer due to CHEK2(*) 1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55-59, 2002.
21. Ohgaki H: Genetic pathways to glioblastomas. Neuropathology 25:1-7, 2005.
22. Ohgaki H, Kleihues P: Epidemiology and etiology of gliomas. Acta Neuropathol 109:93-108, 2005.
23. Ohgaki H, Kleihues P: Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479-489, 2005.
24. Sallinen SL, Ikonen T, Haapasalo H, Schleutker J: CHEK2 mutations in primary glioblastomas. J Neurooncol 74:93-95, 2005.
25. Scott JN, Rewcastle NB, Brasher PM, Fulton D, MacKinnon JA, Hamilton M, Cairncross JG, Forsyth P: Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 46:183-188, 1999.
26. Shapiro MB, Senapathy P: RNA splice junctions of different classes of eukaryotes: Sequence statistics and functional implications in gene expression. Nucleic Acids Res 15:7155-7174, 1987.
27. Shinojima N, Kochi M, Hamada J, Nakamura H, Yano S, Makino K, Tsuiki H, Tada K, Kuratsu J, Ishimaru Y, Ushio Y: The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. J Neurosurg 101:219-226, 2004.
28. Simon M, Köster G, Ludwig M, Mahlberg R, Rho S, Watzka M, Schramm J: Alternative splicing of the p15 cdk inhibitor in glioblastoma multiforme. Acta Neuropathol (Berl) 102:167-1674, 2001.
29. Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, Isaacson S, Rotman M, Asbell SO, Nelson JS: Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: Results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 26:239-244, 1993.
30. Sun G, Gargus JJ, Ta DT, Vickery LE: Identification of a novel candidate gene in the iron-sulfur pathway implicated in ataxia-susceptibility: Human gene encoding HscB, a J-type co-chaperone. J Hum Genet 48:415-419, 2003.
31. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005.
32. Takai H, Naka K, Okada Y, Watanabe M, Harada N, Saito S, Anderson CW, Appella E, Nakanishi M, Suzuki H, Nagashima K, Sawa H, Ikeda K, Motoyama N: Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J 21:5195-5205, 2002.
33. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomaki K, Heikkila P, Holli K, Blomqvist C, Bartek J, Kallioniemi OP, Nevanlinna H: A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 71:432-438, 2002.
34. von Deimling A, Fimmers R, Schmidt MC, Bender B, Fassbender F, Nagel J, Jahnke R, Kaskel P, Duerr EM, Koopmann J, Maintz D, Steinbeck S, Wick W, Platten M, Muller DJ, Przkora R, Waha A, Blumcke B, Wellenreuther R, Meyer-Puttlitz B, Schmidt O, Mollenhauer J, Poustka A, Stangl AP, Lenartz D, von Ammon K: Comprehensive allelotype and genetic anaysis of 466 human nervous system tumors. J Neuropathol Exp Neurol 59:544-558, 2000.
35. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: A cooperative clinical trial. J Neurosurg 49:333-343, 1978.
36. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff J 2nd, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323-1329, 1980.
37. Weller M, Muller B, Koch R, Bamberg M, Krauseneck P; Neuro-Oncology Working Group of the German Cancer Society: Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol 21:3276-3284, 2003.